Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.56 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 2/20 | 0.39 |
| ▸ | CCND1 | P24385 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5334673 | 0.86 | CNR2 (0.43) | CNR2KCNA3CDK4CCND1 | |
| SCHEMBL18247631 | 0.83 | CYP19A1 (0.43) | CNR2KCNA3 | |
| SCHEMBL7808564 | 0.83 | CNR2 (0.39) | CNR2 | |
| SCHEMBL12543158 | 0.82 | CNR2 (0.41) | CNR2CDK4CCND1 | |
| SCHEMBL14411757 | 0.81 | HRH3 (0.47) | CNR2DRD2DRD3 | |
| SCHEMBL23927911 | 0.80 | HTR2C (0.54) | — | |
| SCHEMBL8123525 | 0.79 | CNR2 (0.37) | CNR2 | |
| SCHEMBL27827799 | 0.79 | P2RX7 (0.53) | CNR2TLR8CDK4CCND1 | |
| SCHEMBL28990233 | 0.76 | OXER1 (0.46) | CNR2TLR8CDK4CCND1 | |
| SCHEMBL12542708 | 0.75 | HTR2C (0.58) | CNR2TLR8DRD2DRD3CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9416103-B2 | Use of the aminoalkylindole JWH-073-M4 and related compounds as neutral CB1 receptor antagonists for the treatment of alcoholism, drug abuse, obesity, and obesity-related diseases | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150266820-A1 | USE OF THE AMINOALKYLINDOLE JWH-073-M4 AND RELATED COMPOUNDS AS NEUTRAL CB1 RECPTOR ANTAGONISTS FOR THE TREATMENT OF ALCOHOLISM, DRUG ABUSE, OBESITY, AND OBESITY-RELATED DISEASES | BIOVENTURES, LLC | 2015-09-24 | — | — | US | disclosed |
| WO-2013106349-A1 | USE OF THE AMINOALKYLINDOLE JWH-073-M4 AND RELATED COMPOUNDS AS NEUTRAL CB1 RECPTOR ANTAGONISTS FOR THE TREATMENT OF ALCOHOLISM, DRUG ABUSE, OBESITY, AND OBESITY-RELATED DISEASES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2013-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266820-A1 | USE OF THE AMINOALKYLINDOLE JWH-073-M4 AND RELATED COMPOUNDS AS NEUTRAL CB1 RECPTOR ANTAGONISTS FOR THE TREATMENT OF ALCOHOLISM, DRUG ABUSE, OBESITY, AND OBESITY-RELATED DISEASES | CNR2, CNR1, FAAH | CNR2 1/4885KCNA3 724/4885TLR8 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.